TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03893448

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RECOMBIVAX HB™
Description: A total of 3 RECOMBIVAX HB™ 0.5 mL IM dosings at \~2, \~4, and \~6 months of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VAQTA™
Description: One VAQTA™ 0.5 mL IM dosing at 12 to 15 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAQTA™
Description: One VAQTA™ 0.5 mL IM dosing at 12 to 15 months of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MMR II™
Description: One MMR II™ 0.5 mL subcutaneous (SC) dosing at 12 to 15 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR II™
Description: One MMR II™ 0.5 mL subcutaneous (SC) dosing at 12 to 15 months of age.
Study: NCT05287802

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercises program
Description: Isometric exercises for the quadriceps and hamstrings at home
Study: NCT03893448

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VARIVAX™
Description: One VARIVAX™ 0.5 mL SC dosing at 12 to 15 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VARIVAX™
Description: One VARIVAX™ 0.5 mL SC dosing at 12 to 15 months of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HIBERIX™
Description: One HIBERIX™ 0.5 mL IM dosing at Visit 5.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIBERIX™
Description: One HIBERIX™ 0.5 mL IM dosing at Visit 5.
Study: NCT01547650

Intervention type: OTHER
Intervention: Calculated CVP by using cardiac echogram
Description: Before and after the correction of plasma volume
Study: NCT02378467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7% Hypertonic Saline (HS)
Description: Administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Vios® compressor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Isotonic Saline (IS)
Description: Administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Vios® compressor.
Study: NCT04219800

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Patient-centered counselling and written material
Description: Patient-centered counselling and written material regarding occupational sedentary behaviour, with telephone follow-ups after 1 and 5 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-centered counselling and written material
Description: Patient-centered counselling and written material regarding occupational sedentary behaviour, with telephone follow-ups after 1 and 5 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth
Description: 1. Activity tracker armband (Garmin Vivofit); warns of prolonged sitting and counts daily steps.~2. SMS text messages; reminds of activity breaks.~3. Mobile video instruction for standing pause gymnastics.
Study: NCT00554177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medicane (mifepristone)
Description: 2 doses of 1200mg, Administered 2-3 days apart

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of 1200mg, administered 2-3 days apart
Study: NCT00061945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study: NCT04696224

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: The surgical technique consists in patient in supina position with previous reduction with lower limb traction (on a traction table or manual) associated or not with the use of percutaneous reduction clamps. Longitudinal lateral incision of 3-5 cm proximal to the greater trochanter, approximately 5 cm long, will be performed. After the skin and subcutaneous incision, the fascia lata will be incised in the same direction, with exposure of the gluteal muscles and the proximal femur. The awl will be introduced at the tip of the greater trochanter and then, at the same location, an intramedullary guidewire, towards the proximal shaft, crossing the fracture. A 3 cm incision to the thigh and inferior to the initial incision with template to introduce the screw in the center of the femoral head. Then, a 2cm incision will be made at the distal end of the nail, and a hole in the femur for the distal lock in dynamic nail hole with a 4.5mm drill where a cortical screw will be inserted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: The surgical technique consists in patient in supina position with previous reduction with lower limb traction (on a traction table or manual) associated or not with the use of percutaneous reduction clamps. Longitudinal lateral incision of 3-5 cm proximal to the greater trochanter, approximately 5 cm long, will be performed. After the skin and subcutaneous incision, the fascia lata will be incised in the same direction, with exposure of the gluteal muscles and the proximal femur. The awl will be introduced at the tip of the greater trochanter and then, at the same location, an intramedullary guidewire, towards the proximal shaft, crossing the fracture. A 3 cm incision to the thigh and inferior to the initial incision with template to introduce the screw in the center of the femoral head. Then, a 2cm incision will be made at the distal end of the nail, and a hole in the femur for the distal lock in dynamic nail hole with a 4.5mm drill where a cortical screw will be inserted.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: 30 patients who will not receive the TXA, but will receive a 100ml intravenous saline solution 0,9% after anesthetic induction and before incising the skin (such as group 1) and a compress soaked in saline solution as used in group 2
Study: NCT04540809

Intervention type: OTHER
Intervention: Assessment of strength, proprioception, skill and coordination of the hand
Description: Disease Activity Score 28 was used to determine the disease activity of patients with PsA. Grip strength was measured with the help of Baseline Digital Hand Dynamometer®. Pinch strength was measured with Baseline Hydraulic Pinch Gauge®. Wrist proprioception was assessed by measuring the joint position sensation using a goniometer by actively repeating the target angle predetermined by the researcher (30 ° for flexion and extension, 15 ° for ulnar deviation, 10 ° for radial deviation. Finger skills were assessed using a mobile application called Ball Tap©. The application included the fastest contact of the participants to the balls coming from different parts of the screen for 30 seconds. Two hand coordination and skills were evaluated using the Purdue Pegboard test. The Michigan Hand Outcomes Questionnaire was used for functional evaluation of the hand, and the Health Assessment Questionnaire was used to assess the general functional condition and health-related quality of life.
Study: NCT00489632

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires administered to pediatric patients and their parent(s) or caregiver(s).
Study: NCT03700983

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutri-PEITC jelly
Description: an edible, easily to swallow nutritious gel containing a bioactive compound PEITC
Study: NCT05132062

Intervention type: PROCEDURE
Intervention: Percutaneous Coronary Intervention
Description: Percutaneous Coronary Intervention is a catheter based technique widely used to restore coronary vessel patency. It is performed by fluoroscopic guidance and it requires the use of iodinated contrast medium. The use of iodinated contrast media has been historically linked to AKI occurring within days after their administration and typically referred to as CA-AKI. Furthermore, CA-AKI has been associated with long-term impairment of kidney function, need for renal replacement therapy, and subsequent all-cause mortality.

Intervention type: PROCEDURE
Intervention: Percutaneous Coronary Intervention
Description: Percutaneous Coronary Intervention is a catheter based technique widely used to restore coronary vessel patency. It is performed by fluoroscopic guidance and it requires the use of iodinated contrast medium. The use of iodinated contrast media has been historically linked to AKI occurring within days after their administration and typically referred to as CA-AKI. Furthermore, CA-AKI has been associated with long-term impairment of kidney function, need for renal replacement therapy, and subsequent all-cause mortality.
Study: NCT03232359

Intervention type: DIAGNOSTIC_TEST
Intervention: immature platelets fraction
Description: IPF-% and A-IPC using a reticulocyte detection channel CBC auto analyzer

Intervention type: DIAGNOSTIC_TEST
Intervention: immature platelets fraction
Description: IPF-% and A-IPC using a reticulocyte detection channel CBC auto analyzer

Intervention type: DIAGNOSTIC_TEST
Intervention: immature platelets fraction
Description: IPF-% and A-IPC using a reticulocyte detection channel CBC auto analyzer
Study: NCT03215680

Intervention type: OTHER
Intervention: Climate
Description: Hot and temperate climate

Intervention type: OTHER
Intervention: Climate
Description: Hot and temperate climate
Study: NCT02270320

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: The training is 24 forms Yang-style Tai Chi Chuan exercise, which will perform a 60-minute exercise program, three times per week for 12 weeks.
Study: NCT03830671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18-month regimen containing 6 anti-TB drugs
Description: Investigational regimen:3Am-Mfx-PZA-X-Y-Z/3Am3-Mfx-PZA-X-Y-Z/12 Mfx-PZA-X-Y-Z.X、Y、Z are the drugs susceptible or possibly susceptible to mycobacterial bacilli(The candidated drugs to be selected are:Cs-Cycloserine,Pto-Protionamide,Clr-Clarithromycin,PAS-sodium para-aminosalicylate,E-ethambutol,Bdq-Bedaquiline,Cfz-Clofazimine,Lzd-linezolid).The abbreviation of the name of each drug in the regimen is explained as follows: PZA-pyrazinamide，Am-Amikacin，Mfx-moxifloxacin）and the total duration of the regimen is 18 months
Study: NCT00061945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study: NCT03129893

Intervention type: DEVICE
Intervention: Cuffed tracheal tubes
Description: Cuffed tracheal tube with an anatomically designed high volume - low pressure tube cuff, with a recommendation chart for tube size selection available for pediatric anesthesia
Study: NCT00061945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given PO and as eye drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT, IV, and PO
Study: NCT03665220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ergonomic adjustments
Description: The ergonomic adjustments made were based on a prior assessment of the patient's needs in this respect, using a purpose-made home inspection form .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy plus ergonomic adjustments
Description: This group received, in addition to the ergonomic adjustments described above, sessions of postural orientation and kinesiotherapy (therapeutic exercises).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthcare education
Description: This group received health education information, based on an illustrated manual with advice for patients with chronic stroke.
Study: NCT00061945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trimethoprim-sulfamethoxazole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV and PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acyclovir
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT01031225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA 9090
Description: STA-9090 IV infusion once per week for three consecutive weeks followed by a 1 week dose-free interval
Study: NCT02680730

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Listening Project Protocol
Description: The filtered-music intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Listening Project Protocol
Description: The filtered-music intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
Study: NCT01854515

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone acetate
Study: NCT03220152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emtricitabine / tenofovir 200/300 mg
Description: Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year
Study: NCT04616079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN6490
Description: Single dose of REGN6490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN6490
Description: Single dose of REGN6490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN6490
Description: Single dose of REGN6490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN6490
Description: Single dose of REGN6490
Study: NCT01776645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion Cultivation Training Course
Study: NCT03691038

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 75mg bid
Description: Through the study period, Incremental protocol follows the conventional dose regimen starting pregabaline 75mg bid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 25mg, 50mg
Description: Through the study period, Incremental protocol follows the new dose regimen starting pregabalin 25mg, 50mg
Study: NCT04616079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN6490
Description: Single dose of REGN6490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN6490
Description: Single dose of REGN6490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN6490
Description: Single dose of REGN6490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN6490
Description: Single dose of REGN6490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching single dose of REGN6490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching single dose of REGN6490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching single dose of REGN6490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching single dose of REGN6490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching single dose of REGN6490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching single dose of REGN6490
Study: NCT02958644

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotics
Description: 12g / day synbiotics (fructo-oligosaccharide and probiotics) supplemented orally for 90 days
Study: NCT04616079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching single dose of REGN6490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching single dose of REGN6490
Study: NCT04863326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Making Proud Choices

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Business as usual
Study: NCT02958644

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12g / day placebo (polydextrose) supplemented orally for 90 days
Study: NCT00780091

Intervention type: OTHER
Intervention: classical monitoring strategy
Description: intensive on-site monitoring, consistently with the pharmaceutical industry practices

Intervention type: OTHER
Intervention: optimized monitoring strategy
Description: optimized on-site monitoring, depending on patient's risk
Study: NCT03622125

Intervention type: DIAGNOSTIC_TEST
Intervention: Vital signs
Description: Axillary temperature sampling, at the site of the scorpion sting and the contralateral site with infrared thermometer, and heart rate, respiratory rate and blood pressure on admission, 30 minutes after applying the vial and the medical discharge

Intervention type: DIAGNOSTIC_TEST
Intervention: Vital signs
Description: Axillary temperature sampling, at the site of the scorpion sting and the contralateral site with infrared thermometer, and heart rate, respiratory rate and blood pressure on admission, 30 minutes after applying the vial and the medical discharge
Study: NCT01108172

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Ward
Description: A multidisciplinary team to optimize medical and social care for patients residing in their own homes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The usual care provided to patients after discharge from hospital
Study: NCT03035617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Bupivacaine is long acting local anesthetic drug. Though minimum toxic dose of bupivacaine for intra-peritoneal use is not defined, analgesic effect of its intra-peritoneal use especially after laparoscopic cholecystectomy has been assessed in several interventional studies. Intra-peritoneal use of up to 50ml of .25% , , or up to 20ml of .5% solution has not shown any drug related adverse reactions .

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: In control arm mesh will be soaked in normal saline solution as is routinely done.
Study: NCT04260581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Determination of drug effects through amantadine cessation
Description: Patients will discontinue amantadine, which has been taken since beginning of diagnosis.
Study: NCT03928613

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tablet based Cognitive Training based on location information
Description: Participants perform Tablet based Cognitive training using interactive voice services and tags three times (minimum 30 minutes per time) a week for 6 weeks
Study: NCT01253902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bimatoprost ophthalmic solution 0.01%
Description: One drop of bimatoprost ophthalmic solution 0.01% administered to affected eye(s), once daily in the evening for 12 weeks.
Study: NCT01902849

Intervention type: OTHER
Intervention: blood sampling for IL measurement
Description: Blood sampling to determine interleukins IL6 , IL10 plasma levels are drawn at the following moments:~* T0- before the induction of anesthesia (venous cannula insertion time)~* T1- after induction but before starting surgery~  * In the group I (TIVA -TCI) when the plasma concentration of propofol is 3-3.5 ng/ml~ * In group II (ISOFLURANE) when concentration of isoflurane in exhaled air (Et Isoflurane) is between 0.3-0.5%~* T2, T3- at 2 and 24 hours after surgery

Intervention type: OTHER
Intervention: blood sampling for IL measurement
Description: Blood sampling to determine interleukins IL6 , IL10 plasma levels are drawn at the following moments:~* T0- before the induction of anesthesia (venous cannula insertion time)~* T1- after induction but before starting surgery~  * In the group I (TIVA -TCI) when the plasma concentration of propofol is 3-3.5 ng/ml~ * In group II (ISOFLURANE) when concentration of isoflurane in exhaled air (Et Isoflurane) is between 0.3-0.5%~* T2, T3- at 2 and 24 hours after surgery
Study: NCT04287933

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drain insertion
Description: insertion of a drain
Study: NCT01467323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart
Description: Injected subcutaneously (under the skin) twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic human insulin
Description: Injected subcutaneously (under the skin) twice daily
Study: NCT04320680

Intervention type: OTHER
Group type: OTHER
Intervention: description of a lupus patient cohort
Description: description of a lupus patient cohort
Study: NCT00761839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: After-care summary
Description: The wound care NP will measure the wound and assess adherence to the following self-management activities: visiting the wound care clinic as scheduled; offloading; applying dressings; obtaining assistance at home; and participating in social activities. This information will be entered into a computer database on a VA computer that will generate a summary chart showing the relationship between adherence and wound healing. The generated after-care summary will be discussed with the patient and used to set self-management goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Patients in the control group will receive usual counseling for self-management.